Evotec, a leading drug discovery and development company worldwide, has chosen Navan’s AI-powered platform to replace its older, manual systems for corporate travel and expense management. Employees previously used a mix of tools in different countries, creating confusion and inefficiencies.
The problem with scattered tools
Until recently, Evotec lacked a centralized system for managing travel and expenses. Each region used its own methods, leading to inconsistent practices and a lack of transparency. Employees spent significant time manually entering and reconciling expenses, which slowed down operations and made oversight difficult.
What Navan promises
Navan offers a digital solution that automates expense reconciliation from the moment a transaction is made, starting with a simple card swipe. This approach removes the need for tedious and error-prone manual data entry. Implementation will begin in key markets including Germany, the UK, the U.S., Italy, and France.
Kay Prätorius, VP of Procurement at Evotec, highlighted that the new system will offer better real-time visibility and control over all travel and expense activities. This aligns with Evotec’s broader goals of improving efficiency and making the user experience for staff more seamless.
Zahir Abdelouhab, SVP of Enterprise Sales for EMEA at Navan, noted that companies like Evotec typically see a boost in productivity when they upgrade their systems. He said Navan is helping Evotec by simplifying and standardizing processes, enabling employees to focus more on their core tasks.
Evotec collaborates with all Top 20 pharmaceutical firms and over 800 biotechnology companies. The company focuses on major therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. By adopting Navan’s platform, Evotec is enhancing its complex and dynamic operations across these critical fields.
Evotec operates with a global network of more than 4,500 experts across multiple locations in Europe and the U.S. These teams support drug discovery through various technologies and services, including advanced disease modeling and AI-driven innovation. The company’s commitment to operational agility and scientific excellence is reinforced by this new partnership, which aims to eliminate outdated processes.
The integration of Navan’s platform into Evotec’s workflow aligns with their focus on operational excellence. By using an intuitive, unified system, the company aims to reduce administrative overhead, streamline reporting, and ensure compliance across regions. Employees will benefit from an easier user interface and better access to real-time data, helping them manage their responsibilities more effectively.
With over 100 proprietary R&D assets, most co-owned, Evotec continues to drive innovation in drug discovery. The company combines cutting-edge science with flexible business models to support partners ranging from pharmaceutical giants to academic institutions. This collaboration with Navan is another step toward achieving greater efficiency and precision in operations.